Zhejiang Int'l Group Co

Zhejiang Int'l Group Co Debt Growth

The Year-over-Year Debt Growth of Zhejiang Int'l Group Co (000411.SZ) as of Oct 21, 2026 is -89.85 %. In the previous year, Year-over-Year Debt Growth was -7.36 % — a change of 1,119.96% (lower).

Debt Growth

-89.85 %

YoY

1,119.96%

Last updated:

Year-over-Year Debt Growth of Zhejiang Int'l Group Co is 2025 -89.85 % . Year-over-Year Debt Growth of Zhejiang Int'l Group Co was 2024 -7.36 % . It decreases by 1,119.96% lower compared to the previous year.

The Zhejiang Int'l Group Co Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
1.61 CNY
Jan 1, 2019
-2.12 CNY
Jan 1, 2020
14.26 CNY
Jan 1, 2021
4.94 CNY
Jan 1, 2022
-27.85 CNY
Jan 1, 2023
28.48 CNY
Jan 1, 2024
-7.36 CNY
Jan 1, 2025
-89.85 CNY
The Zhejiang Int'l Group Co Debt Growth history
YEARDebt GrowthYoY
-89.85 %+1,119.96%
-7.36 %-125.86%
28.48 %-202.28%
-27.85 %-664.05%
4.94 %-65.38%
14.26 %-773.86%
-2.12 %-231.71%
1.61 %-99.11%
179.81 %-705.56%
-29.69 %-187.65%
33.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

Year-over-Year Debt Growth of Zhejiang Int'l Group Co is -89.85 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Zhejiang Int'l Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co